Victoria Hamill1, Ian Ford1, Kim Fox2, Michael Böhm3, Jeffrey S Borer4, Roberto Ferrari5, Michel Komajda6, Philippe Gabriel Steg7, Luigi Tavazzi8, Michal Tendera9, Karl Swedberg10. 1. Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom. 2. National Heart and Lung Institute, Imperial College and Institute of Cardiovascular Medicine and Science and Royal Brompton Hospital, London, United Kingdom. 3. Universitätsklinikums des Saarlandes, Klinik für Innere Medizin III, Homburg/Saar, Germany. 4. Division of Cardiovascular Medicine, the Howard Gilman Institute for Heart Valve Disease and the Ronald and Jean Schiavone Institute for Cardiovascular Translational Research, State University of New York Downstate Medical Center, Brooklyn and New York. 5. Department of Cardiology and LTTA Centre, University Hospital of Ferrara and Maria Cecilia Hospital, GVM, Ferrara, Italy. 6. Department of Cardiology, University Pierre et Marie Curie Paris VI, La Pitié-Salpêtrière Hôpital and Institute of Cardio Metabolism ICAN, Paris, France. 7. National Heart and Lung Institute, Imperial College and Institute of Cardiovascular Medicine and Science and Royal Brompton Hospital, London, United Kingdom; DHU FIRE, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Universite Paris-Diderot, Paris, France; INSERM U-1148, Paris, France. 8. Maria Cecilia Hospital-GVM Care and Research, Ettore Sansavini Health Science Foundation, Cotignola, Italy. 9. Medical University of Silesia, Katowice, Poland. 10. National Heart and Lung Institute, Imperial College and Institute of Cardiovascular Medicine and Science and Royal Brompton Hospital, London, United Kingdom; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden. Electronic address: karl.swedberg@gu.se.
Abstract
BACKGROUND: Elevated resting heart rate is associated with increased cardiovascular risk, particularly in patients with left ventricular systolic dysfunction. Heart rate is not monitored routinely in these patients. We hypothesized that routine monitoring of heart rate would increase its prognostic value in patients with left ventricular systolic dysfunction. METHODS: We analyzed the relationship between heart rate measurements and a range of adverse cardiovascular outcomes, including hospitalization for worsening heart failure, in the pooled placebo-treated patients from the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) trial and Systolic Heart failure treatment with the If inhibitor ivabradine (SHIFT) Trial, using standard and time-varying covariate Cox proportional hazards models. By adjusting for other prognostic factors, models were fitted for baseline heart rate alone or for time-updated heart rate (latest heart rate) alone or corrected for baseline heart rate or for immediate previous time-updated heart rate. RESULTS:Baseline heart rate was strongly associated with all outcomes apart from hospitalization for myocardial infarction. Time-updated heart rate increased the strengths of associations for all outcomes. Adjustment for baseline heart rate or immediate previous time-updated heart rate modestly reduced the prognostic importance of time-updated heart rate. For hospitalization for worsening heart failure, each 5 beats/min increase in baseline heart rate and time-updated heart rate was associated with a 15% (95% confidence interval, 12-18) and 22% (confidence interval, 19-40) increase in risk, respectively. Even after correction, the prognostic value of time-updated heart rate remained greater. CONCLUSIONS: In patients with left ventricular systolic dysfunction, time-updated heart rate is more strongly related with adverse cardiovascular outcomes than baseline heart rate. Heart rate should be measured to assess cardiovascular risk at all assessments of patients with left ventricular systolic dysfunction.
RCT Entities:
BACKGROUND: Elevated resting heart rate is associated with increased cardiovascular risk, particularly in patients with left ventricular systolic dysfunction. Heart rate is not monitored routinely in these patients. We hypothesized that routine monitoring of heart rate would increase its prognostic value in patients with left ventricular systolic dysfunction. METHODS: We analyzed the relationship between heart rate measurements and a range of adverse cardiovascular outcomes, including hospitalization for worsening heart failure, in the pooled placebo-treated patients from the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) trial and Systolic Heart failure treatment with the If inhibitor ivabradine (SHIFT) Trial, using standard and time-varying covariate Cox proportional hazards models. By adjusting for other prognostic factors, models were fitted for baseline heart rate alone or for time-updated heart rate (latest heart rate) alone or corrected for baseline heart rate or for immediate previous time-updated heart rate. RESULTS: Baseline heart rate was strongly associated with all outcomes apart from hospitalization for myocardial infarction. Time-updated heart rate increased the strengths of associations for all outcomes. Adjustment for baseline heart rate or immediate previous time-updated heart rate modestly reduced the prognostic importance of time-updated heart rate. For hospitalization for worsening heart failure, each 5 beats/min increase in baseline heart rate and time-updated heart rate was associated with a 15% (95% confidence interval, 12-18) and 22% (confidence interval, 19-40) increase in risk, respectively. Even after correction, the prognostic value of time-updated heart rate remained greater. CONCLUSIONS: In patients with left ventricular systolic dysfunction, time-updated heart rate is more strongly related with adverse cardiovascular outcomes than baseline heart rate. Heart rate should be measured to assess cardiovascular risk at all assessments of patients with left ventricular systolic dysfunction.
Authors: Manuel Martínez-Sellés; Pablo Díez-Villanueva; Jesús Álvarez Garcia; Andreu Ferrero-Gregori; Miquel Vives-Borrás; Fernando Worner; Alfredo Bardají; Juan F Delgado; Rafael Vázquez; José R González-Juanatey; Francisco Fernández-Aviles; Juan Cinca Journal: Clin Cardiol Date: 2018-07-23 Impact factor: 2.882
Authors: Ify R Mordi; Bernadet T Santema; Mariëlle Kloosterman; Anna-Maria Choy; Michiel Rienstra; Isabelle van Gelder; Stefan D Anker; John G Cleland; Kenneth Dickstein; Gerasimos Filippatos; Pim van der Harst; Hans L Hillege; Marco Metra; Leong L Ng; Wouter Ouwerkerk; Piotr Ponikowski; Nilesh J Samani; Dirk J van Veldhuisen; Aeilko H Zwinderman; Faiez Zannad; Adriaan A Voors; Chim C Lang Journal: Clin Res Cardiol Date: 2019-01-04 Impact factor: 5.460
Authors: Katherine E Kurgansky; Petra Schubert; Rachel Parker; Luc Djousse; Jerome B Riebman; David R Gagnon; Jacob Joseph Journal: BMC Cardiovasc Disord Date: 2020-02-26 Impact factor: 2.298